Sign in to view content

Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial

Diana V Do, MD, FASRS

Video
Published 2024

Related

Treatment Switch From Aflibercept to Ranibizumab Pre-filled Syringe in Canadian nAMD and DME Patients in a Real-World Setting: The PRECISE Study
Ananda Kalevar, MD, FRCS(C), DABO
On Demand Cases, Courses, and Papers
2020
Investigation of Microbial Content of Face Masks Used by Patients Receiving Intravitreal Injections
Avinash V Honasoge, MD, PhD
Annual Meeting Talks
2021
An Analysis of Particle Contamination and Protein Aggregation From Syringes Used for Intravitreal Injection
Jason Noble, MD, FRCSC
On Demand Cases, Courses, and Papers
2021

Category: Retinal Vascular Disease

See more